We used the same cores within our TMAs to assess both Her2 amplification and expression, so that we can reliably exclude that different tumor areas were chosen for immunohistochemical and FISH analysis, and rather consider our observation as a tumorbiological true finding. This evidence concerns the gene ERBB2 and neoplasm.